Cargando…
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study
OBJECTIVES: To evaluate the efficacy and safety of subcutaneous golimumab as add-on therapy in patients with active rheumatoid arthritis (RA) despite disease-modifying antirheumatic drug (DMARD) treatment. To evaluate an intravenous plus subcutaneous (IV+SC) golimumab strategy in patients who had no...
Autores principales: | Combe, Bernard, Dasgupta, Bhaskar, Louw, Ingrid, Pal, Sarvajeet, Wollenhaupt, Jürgen, Zerbini, Cristiano A F, Beaulieu, Andre D, Schulze-Koops, Hendrik, Durez, Patrick, Yao, Ruji, Vastesaeger, Nathan, Weng, Haoling H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112444/ https://www.ncbi.nlm.nih.gov/pubmed/23740226 http://dx.doi.org/10.1136/annrheumdis-2013-203229 |
Ejemplares similares
-
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
por: Vastesaeger, Nathan, et al.
Publicado: (2016) -
Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)
por: Weinstein, Cindy L J, et al.
Publicado: (2023) -
Where is biological therapy going?
por: Schulze-Koops, Hendrik, et al.
Publicado: (2000) -
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
por: Schiff, Michael, et al.
Publicado: (2017) -
Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)